Lerner Research Institute News
Read about the latest advances from Lerner Research Institute scientists, including new findings, grant awards, innovations and collaborations.
A research collaboration between Cleveland scientists from Lerner Research Institute and Case Comprehensive Cancer Center uncovers for the first time how two proteins work together to drive triple-negative breast cancer (TNBC), a lethal type of breast cancer with particularly poor prognosis. The researchers say discovery of this pro-cancer pathway offers a potential target for new treatment strategies, which are desperately needed for a class of cancer which is resistant to all current standard of care therapies.
Previous research has established that a protein called WAVE3 contributes to the growth and spread of tumors in many types of cancer, including breast cancers. The current study, published in Oncotarget, explains how and why this happens in TNBC. The key, the team of researchers, led by Khalid Sossey-Alaoui, PhD, Department of Molecular Cardiology, discovered, is WAVE3's association with cancer stem cells (CSCs)—an aggressive class of cancer cells that self-replicate and rapidly grow and spread.
In search of how WAVE3 works, the researchers "turned off" WAVE3 expression in TNBC cell lines using the CRISPR/Cas9 gene editing technology. They observed that compared to control cells, the WAVE3 knockout cancer cells migrated and invaded healthy cells at a significantly reduced rate. Silencing WAVE3 also resulted in markedly fewer CSCs and reduced expression of three genes well-associated with the dangerous cells.
Since resistance to therapy is a key characteristic of CSCs, the researchers next investigated whether turning off WAVE3, and thereby reducing the population of CSCs, may make TNBC cells more sensitive to treatment. They found that WAVE3 knockout cells exposed to radiation formed significantly fewer new colonies than the control cells, an indicator of thwarted metastasis. Taken together, these findings suggest WAVE3 is an important disease moderator, and that inhibiting its expression may help to disarm some of the hallmark pro-cancer defense mechanisms that enable CSCs to evade treatment.
A series of protein expression and staining analyses revealed, however, that WAVE3 does not act alone. WAVE3 and YB1, a CSC-specific transcription factor, work together to drive disease. The YB1 protein can be found in both a cell's cytoplasm and nucleus. It is most dangerous when it is in the nucleus, as this is where it transcribes and "turns on" the CSC genes. The team found that it is when WAVE3 binds to YB1 that YB1 translocates to the nucleus.
Dr. Sossey-Alaoui believes that preventing YB1 from reaching the nucleus, then, may be one novel approach to treating TNBC. More research is needed, but identification of this pathway suggests that drugs that either inhibit WAVE3 expression or prevent WAVE3/YB1 binding may prove an effective disease therapy.
Kamila Bledzka, PhD, is first author on the study, which was supported by grants from the National Heart, Lung, and Blood Institute to Edward Plow, PhD. Dr. Plow is chair of the Department of Molecular Cardiology and holds the Robert C. Tarazi, MD, Endowed Chair in Heart and Hypertension Research.
Photo: WAVE3 and YB1 are shown to co-localize to the nucleus.